Positive news for those cautious about being vaccinated

Positive news for those cautious about being vaccinated

Having just received my first COVID-19 jab this morning, I am encouraged to read the latest stats out of the US Centers for Disease Control and Prevention (CDC). In its recent report, the CDC has found less than 1,000 cases of COVID-19 required hospitalisation out of more than 100 million fully vaccinated individuals.

The CDC report records “breakthrough infections” which are positive COVID-19 cases in individuals 14 days after all recommended doses of a vaccine.

The CDC report into approximately 101 million fully vaccinated individuals in the United States at April 30, 2021, found officially recorded only 10,262 breakthrough infections.

Twenty-five per cent of the breakthrough infections were classified as asymptomatic. Hospitalisations occurred in just 995 infections and 160 individuals died. The average age of those who died was 82, and one fifth of the deaths were reported as potentially unrelated to COVID-19.

Table 1.  CDC findings as at April 30, 2021

Screen Shot 2021-05-31 at 12.33.59 pm

This latest report follows a CDC study of mRNA COVID-19 vaccines in those aged over 65. That report found vaccination reduced the risk of hospitalisation from COVID-19 in over-65s  by 94 per cent.

The CDC is at pains to remind readers undercounting in its latest study is probable, stating, “…the number of reported COVID-19 vaccine breakthrough cases is likely a substantial undercount of all SARS-CoV-2 infections among fully vaccinated persons,” the report states. “The national surveillance system relies on passive and voluntary reporting, and data might not be complete or representative. Many persons with vaccine breakthrough infections, especially those who are asymptomatic or who experience mild illness, might not seek testing.”

Particularly encouraging however are the findings among all breakout cases, not just hospitalised cases. The CDC again; “Before we started only studying breakthrough infections in only hospitalised patients, we were studying all breakthrough infections. What we were starting to find is a large portion of them were fully asymptomatic and in fact when we went to study them and sequence them there was inadequate virus to even do so.”

In an earlier report published April 2, 2021 the CDC studied almost 4,000 vaccinated healthcare personnel, first responders, and other essential and frontline workers finding Pfizer-BioNTech and Moderna’s vaccines prevented 80 per cent of cases after the first dose and 90 per cent after the second dose.

In a separate announcement, Pfizer-BioNTech said that its ongoing phase-three clinical trial of the mRNA vaccine reveals strong immunisation persists for at least six months among vaccinated individuals.

INVEST WITH MONTGOMERY

Roger Montgomery is the Founder and Chairman of Montgomery Investment Management. Roger has over three decades of experience in funds management and related activities, including equities analysis, equity and derivatives strategy, trading and stockbroking. Prior to establishing Montgomery, Roger held positions at Ord Minnett Jardine Fleming, BT (Australia) Limited and Merrill Lynch.

This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.

Why every investor should read Roger’s book VALUE.ABLE

NOW FOR JUST $49.95

find out more

SUBSCRIBERS RECEIVE 20% OFF WHEN THEY SIGN UP


Post your comments